Same Drug, Different Strength or Form? Check the Exact Product on the Formulary

A prescriber writes for a strength or dosage form of a drug that the plan's drug list plainly includes, and the pharmacy claim still does not pay as expected. The usual explanation is not a system error. Published formularies list products line by line—drug name, dosage form and the strengths printed on that line—and the pharmacy claim is adjudicated against the identifier of the product actually dispensed. A molecule appearing on the list does not show that every strength or form of it is covered.

flowchart TD
  A["Prescription: drug, dosage form, strength"] --> B["Find the drug in the current formulary edition"]
  B --> C{"Is this form and strength printed on the line?"}
  C -->|"Yes"| D{"Flag or NDC note on the line?"}
  C -->|"No"| E{"Closed or open formulary?"}
  D -->|"None"| F["Submit the 11-digit identifier of the product dispensed"]
  D -->|"PA, ST or QL"| G["Meet the plan criteria or request prior authorization"]
  D -->|"Excluded NDCs"| H["Confirm the specific product is not excluded"]
  G --> F
  H --> F
  E -->|"Closed"| I["Expect a Product Not on Formulary reject"]
  E -->|"Open"| J["Expect non-formulary messaging and possibly higher patient pay"]
  I --> K["Prescriber: choose a listed product or request a formulary exception"]
  J --> K
  I --> L["Part D only: check transition-fill eligibility"]
  F --> M{"Claim response"}
  M -->|"Paid"| N["Dispense as prescribed"]
  M -->|"Dose optimization reject"| O["Prescriber decides on a higher-strength once-daily prescription"]
  M -->|"Plan limits exceeded"| P["Correct claim data or seek a quantity-limit exception"]

How a formulary line is written: name, form, strengths

CVS Caremark publishes its Value Formulary as a PDF organized by therapeutic class. Two editions were posted when this article was checked on October 19, 2026: the current edition, dated 10/01/2026 (document 106-25954B 100126), and an upcoming edition effective January 1, 2027 (106-25954B 010127). Both explain the convention. The first column lists the drug name; brand-name drugs are capitalized (the document's example is LIPITOR), generic drugs appear in lower-case italics (atorvastatin), and a Requirements/Limits column carries any coverage conditions.

Each generic line then names one or more dosage forms—abbreviations such as caps, tabs, chew, susr, soln, conc, tb12, tb24 and tbec—each followed by the strengths printed for that form. The lines below are quoted from both editions; none of them changed between 10/01/2026 and 01/01/2027.

• Gabapentin: “gabapentin caps 100mg, 300mg, 400mg; tabs 600mg, 800mg”. One line, two forms, five strengths. The line prints 300 mg only as a capsule and prints no oral liquid.

• Amoxicillin: “amoxicillin caps 250mg, 500mg; chew 125mg, 250mg; susr 125mg/5ml, 200mg/5ml, 250mg/5ml, 400mg/5ml; tabs 500mg, 875mg”. Four dosage forms, each with its own strength list. The chewable tablet is printed at 125 mg and 250 mg only, and 500 mg appears as both a capsule and a tablet.

• Bupropion: three separate lines in the antidepressant section—“bupropion tabs 75mg, 100mg”, “bupropion hcl tb12 100mg, 150mg, 200mg” and “bupropion hcl ext-rel tb24 150mg, 300mg”—plus “bupropion hcl (smoking deterrent) tb12 150mg” under smoking deterrents. The release profile is part of the product's identity: 150 mg appears on three different lines.

• Diclofenac sodium: “diclofenac sodium delayed-rel tbec 25mg, 50mg, 75mg” and “diclofenac sodium ext-rel tb24 100mg”. Delayed-release and extended-release tablets are separate lines with different strength sets.

• Colchicine: “colchicine caps .6mg; tabs .6mg”. The same 0.6 mg strength is printed in two forms, so strength alone does not identify the product.

• Escitalopram and sertraline: “escitalopram oxalate soln 5mg/5ml; tabs 5mg, 10mg, 20mg” and “sertraline hcl conc 20mg/ml; tabs 25mg, 50mg, 100mg”. A liquid and a tablet share one line but remain different products with different strength expressions.

The legend defines the flags: AGE (age limit), OTC (over the counter), PA (prior authorization), PA* (“If Quantity Limit is exceeded, Prior Authorization may apply”), PA** (“If Step Therapy requirements are not met, Prior Authorization may apply”), QL (quantity limit), SP (drug subject to Specialty Guideline Management) and ST (step therapy). None of the lines above carries a flag in either edition. Elsewhere, flags differ by form and strength of the same drug: “tramadol hcl tabs 50mg” carries “QL; PA*”, while “tramadol hcl tb24 100mg, 200mg, 300mg” carries “QL; PA*, Initial PA may apply to higher strengths”. The plan-design text adds a form-level rule for opioids: members who are opioid-naïve must use an immediate-release formulation before moving to an extended-release one.

Some lines go below the level of form and strength. The extended-release metformin line, “metformin ext-rel tb24 500mg, 750mg”, is annotated “Listing does not include generics for FORTAMET and GLUMETZA”, and “paroxetine hcl ext-rel tb24 12.5mg, 25mg, 37.5mg” is annotated “Listing does not include certain NDCs”. A product can match the printed name, form and strength and still fall outside the listing, which is the practical reason to check the exact product rather than its description. For reading the labeler, product and package segments of an NDC, see our NDC lookup workflow for claims teams.

The identity matrix: 10/01/2026 and 01/01/2027 editions

The matrix lays the same lines side by side across both editions, with flags exactly as printed and what each line does not show. It is a verification aid for reading a formulary entry, not a switching guide. Nothing in it suggests splitting, combining or substituting tablets, and any change to the product prescribed is a prescriber decision.

Two patterns stand out. Identical strengths do not imply an identical product: 0.6 mg colchicine is printed as both capsule and tablet, 500 mg amoxicillin as both capsule and tablet, and 150 mg bupropion on three lines with different release profiles. And a line can be narrower than its description: the metformin and paroxetine extended-release lines name their forms and strengths and still exclude some products.

What changed between the two editions

The matrix rows are unchanged, but a line-by-line comparison of the two PDFs shows strength and form changes elsewhere, including the three below—the kind a molecule-level search would miss.

In each case the molecule stays on the list while the printed strength or form set changes. CVS notes that the document “is updated periodically and changes may appear prior to their effective date to allow for client notification”, so the upcoming file should be rechecked again before January 1, 2027. Whether a particular plan adopts a change depends on that plan's benefit design.

What the pharmacy claim checks

The 2026 CVS Caremark Provider Manual sets out the network pharmacy rules behind those lines. Claims go through the Caremark adjudication system using a current HIPAA-named version of the NCPDP Telecommunication Standard (section 4.02, items 6 and 7). Item 13 of the same section requires the pharmacy to submit “the precise eleven (11) digit Product Identifier for the Covered Item dispensed”, and the manual's definitions give the 11-digit NDC as an example of a product identifier. Claims submitted with a different identifier “are subject to audit review and Chargeback and are not eligible for reimbursement.”

The manual then lists the responses a pharmacy may see. Each is described as a “following or similar” message, so plan sponsors can vary the wording.

The step-therapy wording is telling: the reject names the NDC, not the molecule. For quantity rejects that arrive after a prior authorization was approved, see Prior Authorization Approved but Quantity Rejected.

Rules that close off claim-data workarounds

• No editing claim data to pass an edit. Section 4.02, item 8: the pharmacy “must not take any steps to circumvent Plan design or claim edits”, must not modify claim fields such as quantity or days' supply to bypass edits, and must not use a Submission Clarification Code, prior authorization number, Eligibility Clarification Code or other data element to inappropriately override a reject. Section 4.03, item 1(c), adds that the quantity dispensed must not be adjusted to circumvent adjudication edits.

• The strength on the claim must match the prescription. Section 4.03, item 2: the strength on the claim “must be an accurate reflection of that which was prescribed”, or documentation of the unavailability of the prescribed strength will be required. The pharmacy uses the strength originally prescribed or an available higher-strength single dose as described in the dose-optimization section, and “must not utilize a lesser strength in an increased quantity without documentation of unavailability of the prescribed strength.”

• Changes to the prescription need the prescriber. Section 4.02, item 10: any change to a prescription, including the item prescribed or the directions for use, must be approved by the prescriber before dispensing, with the approval dated and documented on the prescription record.

• Formularies take precedence over pharmacy programs. Section 5.05: the pharmacy agrees not to implement substitution programs that are inconsistent with the plan's therapeutic programs and formularies.

Taken together, these rules mean a mismatch between the prescribed product and the printed line cannot be fixed at the pharmacy keypad. It is resolved by the prescriber choosing a listed product or by a documented exception.

Dose optimization: when the plan asks for a different strength

Section 5.08 runs in the other direction. Dose optimization is “a point-of-service claim reject for selected drugs where multiple daily doses of the drug are prescribed and where a higher strength single daily dose is available and clinically appropriate.” The manual's example is Lipitor 10 mg at two tablets a day, which “could be optimized to Lipitor 20 mg 1 tab/day”; the Value Formulary's atorvastatin line prints 10 mg, 20 mg, 40 mg and 80 mg tablets. The pharmacy contacts the prescriber for a new prescription at the higher once-daily strength and resubmits. If that cannot or should not be done in the pharmacist's professional judgment, or the prescriber will not change the prescription, the manual points to the claim messaging, which may offer a help-desk override. The manual does not list which drugs the program covers, so the reject itself is the signal. For dose changes that collide with refill timing, see Dose Change Before Refill Day.

The Medicare Part D floor for strengths and dosage forms

Commercial formularies such as the Value Formulary are shaped by plan sponsors and their PBMs. Medicare Part D adds federal rules that speak directly to strengths and dosage forms, and they show both the protections and their limits.

• Formulary adequacy. Under 42 CFR 423.120(b)(2)(i), a Part D formulary must include within each therapeutic category and class at least two Part D drugs that are not therapeutically equivalent and bioequivalent, “with different strengths and dosage forms available for each of those drugs”, subject to the exceptions the regulation lists.

• Two drugs means two molecules. Chapter 6 of CMS's Medicare Prescription Drug Benefit Manual says the two-drug minimum must be met with two chemically distinct drugs; sponsors do not meet it “by including only two dosage forms or strengths of the same drug, or a brand name drug and its generic equivalent.” The same passage adds that “multiple strengths and dosage forms should also be available for each covered drug”, including forms commonly used in long-term care and home infusion. Section 30.2.3 names unit-dose, liquid, chewable and parenteral preparations as long-term-care forms CMS expects sponsors to cover.

• A prior authorization approval follows the drug across strengths. CMS “expects that, with rare exceptions, the sponsor's approval of a PA or ST for one strength of a drug for a beneficiary will apply to all strengths.” Unless dose-specific criteria were submitted to and approved by CMS, sponsors must not implement dose-level requirements. This is Part D guidance; commercial plans are not bound by it.

• Specialty-tier placement is set strength by strength. Sponsors evaluate negotiated prices “at the drug product strength, package size, and formulation level”, and CMS only allows onto the specialty tier those strengths, package sizes and formulations that would reasonably exceed the dollar-per-month threshold. Two strengths of one drug can therefore sit on different tiers.

• Protected classes still have form exceptions. For the six protected classes (immunosuppressants for transplant rejection prophylaxis, antidepressants, antipsychotics, anticonvulsants, antiretrovirals and antineoplastics), “substantially all” means all drugs and unique dosage forms are expected on the formulary. The exceptions include extended-release products when the immediate-release product is included, and “dosage forms that do not provide a unique route of administration (e.g., tablets and capsules versus tablets and transdermals).” Even in a protected class, a listed tablet does not oblige the plan to list the capsule.

The Chapter 6 passages quoted here carry CMS revision stamps from 2008 and 2016; the regulation text is from the current eCFR edition of 42 CFR 423.120.

Part D also protects people already taking a drug. Under 42 CFR 423.120(b)(3), sponsors must run a transition process for enrollees prescribed drugs that are not on the formulary, including formulary drugs that require prior authorization or step therapy. It applies to new enrollees after the annual election period, people newly eligible from other coverage, people who switch plans after the contract year starts, and current enrollees affected by formulary changes. Within the first 90 days of coverage, the plan must provide a one-time temporary supply of at least an approved month's supply and send written notice within three business days after the temporary fill is adjudicated. Caremark's manual (section 10.05.08) applies transition fills to non-formulary products, products requiring prior authorization or step therapy, and quantity or daily-dose limits that are not safety related. Eligible claims pay on first submission with messages such as “Paid under Transition Fill - Non-formulary”. Products excluded from Part D are not eligible.

When a Part D plan makes a negative formulary change, the written notice required by 42 CFR 423.120(f)(4) must name the affected drug and state whether it is being removed, moved to a higher cost-sharing tier, or given new or stricter prior authorization, step-therapy or quantity requirements. It must also give the reason, list formulary alternatives in the same or a lower tier with their expected cost sharing and, for most changes, explain how to request a coverage determination, including an exception. Our article on formulary change notices covers what such a notice does and does not decide.

Legitimate paths when the exact product is not listed

When the prescribed strength or form is not on the line, or the claim response says so, the documented routes run in roughly this order. None of them involves editing claim data, and none of them is a pharmacy-only decision.

1. Confirm the line and the edition. Find the drug in the current edition, read the dosage-form abbreviation and strengths on its line, check the Requirements/Limits column and any NDC note, and confirm which formulary the member's plan actually uses. A molecule-level match is not a product-level match.

2. Bring the prescriber the listed options. Caremark's manual expects the pharmacy to tell the member when a non-formulary drug has been prescribed and to contact the prescriber. Moving to a listed form or strength is a prescribing decision, made through a new prescription or a documented prescriber-approved change.

3. Request a formulary exception. Both editions of the Value Formulary state: “If a medication is not listed on the document, a formulary exception may be requested for coverage.” Such requests are reviewed against drug-specific prior authorization criteria or standard non-formulary request criteria. For Medicare drug plans, Medicare.gov says the prescriber's supporting statement should explain that the drug is medically necessary, that a different drug would cause negative health effects, or that a different drug would be less effective. Formulary Exception vs Prior Authorization covers which request fits which situation.

4. Use prior authorization where the line carries PA, PA* or PA**. The prescriber supplies documentation against the plan's criteria. In Part D, CMS expects an approval for one strength to apply to all strengths, with rare exceptions and unless dose-specific criteria were approved.

5. Use a quantity-limit exception when quantity, not identity, is the problem. Medicare.gov's example of a quantity limit is a plan covering only 30 tablets of a drug per month; an exception can be requested if the prescriber believes the limit is not medically appropriate, for example because a higher dose is needed. Under Caremark's manual, the pharmacy may also ask the help desk for an override where the plan sponsor allows it.

6. Check Part D transition-fill eligibility. For an eligible Medicare enrollee, a transition fill bridges the gap while the exception or prior authorization is pursued. Medicare.gov describes it as a one-time, 30-day supply of a drug the enrollee has been taking that the plan does not cover or that requires prior authorization or step therapy.

7. Treat a supply shortage as a documentation question. Caremark's manual allows a lesser strength in a larger quantity only with documented unavailability of the prescribed strength, and any change to the prescription still needs prescriber approval. It is not a way around a coverage edit.

Where the printed line still is not the answer

A matching line is strong evidence, but the Value Formulary itself limits what it promises. Its plan-design section states that “Generics listed in therapeutic categories are for representational purposes only”, that “Individual pharmacy benefit plans may impose restrictions or not reimburse some products”, and that a member's plan design “may not cover certain medications, products, or categories, regardless of their appearance in this document.” The preface adds that some plan designs “may alter coverage of certain products or vary copay amounts based on the condition being treated.” The document is a standard template; client-specific formularies and other PBMs list products differently.

Coverage of the same drug also differs from plan to plan. An analysis in the American Journal of Managed Care used Fingertip Formulary data downloaded in May 2011 for 1,768 US health plans and three drug classes (statins, angiotensin II receptor blockers and protein-tyrosine kinase inhibitors). It found that the share of on-patent drugs placed in the two lowest copay tiers “varies dramatically between insurance types”, with Medicare plans covering fewer on-patent drugs in those tiers than commercial plans. The study worked at the class and tier level rather than the strength level, and it is a 2011 snapshot. Its relevance here is narrower: a line read from one formulary does not transfer to another plan.

Benefit routing adds another layer. A study in the Journal of Managed Care & Specialty Pharmacy used specialty drug coverage policies current as of August 2020 from 17 of the largest US commercial health plans. Eight issued separate medical and pharmacy benefit policies for the same specialty drug and indication. Of 1,619 medical–pharmacy policy pairs, 86% were concordant and 14% (233) were discordant, most often because of step therapy (184 of 233), followed by prescriber requirements (52) and patient subgroups (25). Where the pairs disagreed, the pharmacy policy was more restrictive 54% of the time and the medical policy 41% of the time. For a product that can be billed under either benefit, the identity check has to include which benefit is being billed.

Finally, the edition matters. The upcoming Value Formulary is already posted, and the comparison above shows strength and form changes ahead of its January 1, 2027 effective date. Before a plan year turns, recheck the exact line for each product a patient population depends on, and do the same when a formulary change notice arrives rather than relying on a molecule search.

Sources

• CVS Caremark — Value Formulary, current edition (dated 10/01/2026): formulary lines, legend, plan-design and notice text quoted for the current edition; checked October 19, 2026.

• CVS Caremark — Value Formulary, effective January 1, 2027 (upcoming edition): the same lines in the upcoming edition and the strength and form changes compared above.

• CVS Caremark — 2026 Caremark Provider Manual: claim-submission rules (sections 4.02 and 4.03), formulary, prior authorization, quantity, dose-optimization and step-therapy messages (sections 5.05 to 5.09) and Part D transition fills (section 10.05.08).

• eCFR — 42 CFR 423.120: Access to covered Part D drugs: formulary adequacy (b)(2)(i), transition process (b)(3) and written-notice content (f)(4).

• Centers for Medicare & Medicaid Services — Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements: two-drug minimum, strengths and dosage forms, prior authorization across strengths, specialty tiers, long-term-care dosage forms and protected classes.

• Medicare.gov — Drug plan rules: exceptions and supporting statements, quantity limits and transition fills for Medicare drug plans.

• American Journal of Managed Care — How Does Drug Coverage Vary by Insurance Type? Analysis of Drug Formularies in the United States: Régnier SA. Am J Manag Care. 2014;20(4):322-331. Tier placement of on-patent drugs across 1,768 plans, using May 2011 data.

• Journal of Managed Care & Specialty Pharmacy — Specialty drug coverage varies between health plans' medical and pharmacy benefit policies: Levine AA, Panzer AD, Kauf TL, et al. J Manag Care Spec Pharm. 2023;29(6):607-613. Medical versus pharmacy policy concordance, policies current as of August 2020.